Cargando…

Financial toxicity differences between chemical versus surgical androgen deprivation therapy

Detalles Bibliográficos
Autores principales:	Aragon-Ching, Jeanny B., Rosner, Inger L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641061/ https://www.ncbi.nlm.nih.gov/pubmed/36386267 http://dx.doi.org/10.21037/tau-22-588

Ejemplares similares

Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort
por: Paul, Charles J., et al.
Publicado: (2022)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Assessment of real-world application of advanced prostate cancer management in Japan
por: Aragon-Ching, Jeanny B.
Publicado: (2022)

A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy
por: Yuan, Fan, et al.
Publicado: (2023)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2023)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Key Difficulties Associated with Cancer Biology
por: Fang, Xiaolan, et al.
Publicado: (2016)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Safety first: evidence for delay of radical prostatectomy without use of androgen deprivation therapy during COVID-19
por: Sean Ong, Xuan Rui, et al.
Publicado: (2020)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?
por: Salih Semiz, Huseyin, et al.
Publicado: (2022)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice
por: Poulsen, Christian Bo, et al.
Publicado: (2016)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Value and Financial Toxicity of New Cancer Drugs
por: Wickham, Rita J.
Publicado: (2016)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_69cdvi8ugao2l2t7a7us4tco9i